VR Adviser
Latest statistics and disclosures from VR Adviser's latest quarterly 13F-HR filing:
- Top 5 stock holdings are APGE, OCUL, ELVN, VRDN, APLT, and represent 46.33% of VR Adviser's stock portfolio.
- Added to shares of these 9 stocks: Oruka Therapeutics (+$76M), Artiva Biotherapeutics (+$25M), CASI (+$5.4M), ENGN, APLT, TIL, TENX, VRDN, TRVI.
- Started 4 new stock positions in Oruka Therapeutics, TIL, TENX, Artiva Biotherapeutics.
- Reduced shares in these 7 stocks: EWTX (-$22M), MRUS (-$18M), ZURA (-$16M), DNTH (-$9.6M), ARVN, ABIO, ATXS.
- Sold out of its position in ABIO.
- VR Adviser was a net buyer of stock by $42M.
- VR Adviser has $1.9B in assets under management (AUM), dropping by 21.59%.
- Central Index Key (CIK): 0001615982
Tip: Access up to 7 years of quarterly data
Positions held by VR Adviser consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for VR Adviser
VR Adviser holds 38 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Apogee Therapeutics (APGE) | 26.1 | $499M | 8.5M | 58.74 |
|
|
| Ocular Therapeutix (OCUL) | 5.8 | $111M | 13M | 8.70 |
|
|
| Enliven Therapeutics (ELVN) | 5.4 | $103M | 4.0M | 25.54 |
|
|
| Miragen Therapeutics (VRDN) | 4.6 | $88M | 3.9M | 22.75 |
|
|
| Applied Therapeutics (APLT) | 4.4 | $84M | +2% | 9.8M | 8.50 |
|
| Spyre Therapeutics Com New (SYRE) | 4.1 | $79M | 2.7M | 29.41 |
|
|
| Dyne Therapeutics (DYN) | 4.1 | $78M | 2.2M | 35.92 |
|
|
| Oruka Therapeutics | 4.0 | $76M | NEW | 3.1M | 24.51 |
|
| Kalvista Pharmaceuticals (KALV) | 3.8 | $72M | 6.2M | 11.58 |
|
|
| Pharvaris N V (PHVS) | 3.3 | $63M | 3.4M | 18.52 |
|
|
| Cogent Biosciences (COGT) | 3.2 | $61M | 5.7M | 10.80 |
|
|
| Dianthus Therapeutics (DNTH) | 2.5 | $48M | -16% | 1.7M | 27.38 |
|
| 4d Molecular Therapeutics In (FDMT) | 2.5 | $48M | 4.4M | 10.81 |
|
|
| Merus N V (MRUS) | 2.4 | $45M | -28% | 908k | 49.96 |
|
| Oric Pharmaceuticals (ORIC) | 2.4 | $45M | 4.4M | 10.25 |
|
|
| Erasca (ERAS) | 2.3 | $44M | 16M | 2.73 |
|
|
| Praxis Precision Medicines I Com New (PRAX) | 2.1 | $41M | 706k | 57.54 |
|
|
| Astria Therapeutics (ATXS) | 2.0 | $38M | -4% | 3.5M | 11.01 |
|
| Terns Pharmaceuticals (TERN) | 1.5 | $28M | 3.4M | 8.34 |
|
|
| Aquestive Therapeutics (AQST) | 1.4 | $28M | 5.6M | 4.98 |
|
|
| Edgewise Therapeutics (EWTX) | 1.4 | $27M | -45% | 1.0M | 26.69 |
|
| Artiva Biotherapeutics | 1.3 | $25M | NEW | 1.6M | 15.45 |
|
| Engene Holdings (ENGN) | 1.2 | $24M | +26% | 3.6M | 6.60 |
|
| Cullinan Oncology (CGEM) | 1.2 | $23M | 1.4M | 16.74 |
|
|
| Mersana Therapeutics (MRSN) | 1.1 | $21M | 11M | 1.89 |
|
|
| Taysha Gene Therapies Com Shs (TSHA) | 0.9 | $18M | 9.0M | 2.01 |
|
|
| Abivax Sa Sponsored Ads (ABVX) | 0.8 | $16M | 1.3M | 11.52 |
|
|
| Trevi Therapeutics (TRVI) | 0.6 | $11M | 3.4M | 3.34 |
|
|
| Arvinas Ord (ARVN) | 0.6 | $11M | -27% | 455k | 24.63 |
|
| Adverum Biotechnologies Com New (ADVM) | 0.5 | $10M | 1.5M | 7.02 |
|
|
| Century Therapeutics (IPSC) | 0.5 | $9.2M | 5.4M | 1.71 |
|
|
| Zura Bio Class A Ord Shs (ZURA) | 0.4 | $8.2M | -66% | 2.0M | 4.06 |
|
| Perceptive Cap Solutions Cor Cl A Ord Shs (PCSC) | 0.4 | $7.5M | 750k | 10.02 |
|
|
| Cabaletta Bio (CABA) | 0.4 | $7.4M | 1.6M | 4.72 |
|
|
| Casi Pharmaceuticals Ord Shs (CASI) | 0.3 | $6.1M | +783% | 987k | 6.16 |
|
| Tenaya Therapeutics (TNYA) | 0.2 | $3.0M | 1.6M | 1.93 |
|
|
| Instil Bio Com New (TIL) | 0.1 | $2.2M | NEW | 33k | 67.32 |
|
| Tenax Therapeutics Com New (TENX) | 0.0 | $721k | NEW | 208k | 3.46 |
|
Past Filings by VR Adviser
SEC 13F filings are viewable for VR Adviser going back to 2020
- VR Adviser 2024 Q3 filed Nov. 14, 2024
- VR Adviser 2024 Q2 filed Aug. 14, 2024
- VR Adviser 2024 Q1 filed May 15, 2024
- VR Adviser 2023 Q4 filed Feb. 14, 2024
- VR Adviser 2023 Q3 filed Nov. 14, 2023
- VR Adviser 2023 Q2 filed Aug. 11, 2023
- VR Adviser 2022 Q2 restated filed May 15, 2023
- VR Adviser 2022 Q3 restated filed May 15, 2023
- VR Adviser 2022 Q4 restated filed May 15, 2023
- VR Adviser 2023 Q1 filed May 15, 2023
- VR Adviser 2022 Q4 filed Feb. 14, 2023
- VR Adviser 2022 Q3 filed Nov. 14, 2022
- VR Adviser 2022 Q2 filed Aug. 15, 2022
- VR Adviser 2022 Q1 filed May 16, 2022
- VR Adviser 2021 Q4 filed Feb. 14, 2022
- VR Adviser 2021 Q3 filed Nov. 15, 2021